Voluson Expert 22, Voluson Expert 20, Voluson Expert 18

The Voluson Expert series (18, 20, 22) represents an advancement in diagnostic ultrasound systems, specializing in OB/GYN and general radiology through high-performance 3D/4D imaging and diverse transducer technology. These systems integrate novel AI-driven software features like SonoPelvicFloor, SonoLyst, and Fetal HS, aiming to improve image analysis, diagnostic support, and workflow efficiency in various clinical applications.

The Voluson Expert series (models 18, 20, and 22) are advanced Track 3 ultrasound systems designed primarily for general radiology and specialized obstetric/gynecological applications, featuring real-time 3D/4D acquisition capabilities. These mobile console systems, equipped with color displays and touch panels, utilize a range of transducers including linear, curved linear, and matrix phased arrays for high-performance imaging across diverse clinical scenarios. The core technology relies on established ultrasonic principles, offering modes such as B-mode, M-mode, Doppler (Pulsed, Continuous Wave, Color, Power), Harmonic Imaging, 3D/4D imaging, Elastography, and Shear Wave Elastography. The systems are intended for use by qualified healthcare professionals in hospital or medical clinic settings for a wide array of diagnostic applications, including fetal/OB, abdominal, pediatric, small organs, cephalic, cardiac, musculoskeletal, vascular, transvaginal, and transrectal imaging. The Voluson Expert series introduces several technological advancements, including a new RIC10-D probe and differentiated model capabilities, with the Expert 22 supporting the 4D electronic probe eM6CG3. Key enhancements involve the integration of Artificial Intelligence (AI) software features aimed at improving workflow and diagnostic performance. These include SonoPelvicFloor for automated pelvic floor plane alignment and measurements, SonoLyst for AI-assisted sorting and grading of fetal anatomical images, and Fetal HS for suggesting optimal fetal heart views (4CH, 3VT) and heart angle measurements. Additional software improvements focus on shadow reduction, image adaptation (Adapt), and fetal heart rate (Sono FHR). Non-clinical testing confirmed the devices' safety (acoustic, biocompatibility, electrical, mechanical) and the AI features demonstrated high success/accuracy rates (typically >70-80%) on diverse datasets, validated by sonographers/clinicians.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of the new AI features (SonoPelvicFloor, SonoLyst, Fetal HS) compare in real-world clinical settings with diverse patient populations and varying operator skill levels, beyond the described test datasets?; What is the specific impact of the 'Shadow Reduction' and 'Adapt' software features on image quality and diagnostic confidence across different tissue types and imaging depths?; Could the AI algorithms, particularly SonoLyst, be trained or adapted to recognize and flag potential fetal anomalies, rather than just sorting and grading standard views?; What are the quantifiable improvements in examination time or diagnostic accuracy attributable to the workflow enhancements from SonoPelvicFloor and SonoLyst compared to traditional manual methods?; How does the new RIC10-D transducer's 'incremental improvement in technology' translate to tangible benefits in image resolution, penetration, or specific clinical applications compared to its predicate, the RIC5-9-D?